



Scan to download a copy of this presentation

Impact on Migraine-related Quality of Life in a non-controlled, real-world Population in the NoRdics treated with AimOVig™ (Erenumab): IMPROVE

Amin FM¹, Edvinsson L², Poole AC³, Sollenberg U⁴, Beyeen A⁴

¹Danish Headache Center, Rigshospitalet Glostrup, Denmark, ²Lund University, Sweden, ³Oslo Hodepinesenter, Norway

⁴Novartis Sweden.

2021 EAN Annual Meeting, June 19-22 | virtual

DISCLOSURES: FMA, LE and ACP report lecturing and/or advisory board fee from Novartis, Teva, Eli Lilly ad Lundbeck. US and AB are employees of Novartis.





Erenumab, a monoclonal antibody against the CGRP receptor, is a novel mechanism-based therapy tailored for migraine prevention. Phase III studies have shown promising results of erenumab in patients who reached the endstage of therapeutical opportunities.

STUDY DESIGN


A 1-year non-interventional phase IV trial, including 195 adult migraine patients on erenumab from 10 headache centers in Denmark, Sweden and Norway.

Primary endpoint
change in HIT-6 score at 12 months compared to baseline.

The study is part of a larger umbrella protocol of studies with near-identical design, allowing for future data pooling. Here, a pre-planned interim analysis of IMPROVE was performed comparing multiple outcomes, including mean HIT-6 scores and mean monthly migraine days (MMD) at month 3 and 6 versus baseline

Here, we present a 6-month interim analysis data on the impact of erenumab on the quality of life in a real-world population study

EXPERIMENTAL FLOW



DEMOGRAPHICS Total (N=159)

Age (years)

Mean (SD)	45.6 (12.7)
Median (Q1, Q3)	47.0 (36.0, 54.0)
Min, Max	18, 77

Sex

Female	135 (84.9%)
Male	24 (15.1%)


Migraine type

EM + aura	0
EM – aura	3 (1.9%)
CM + aura	52 (32.9%)
CM – aura	103 (65.2%)



CONCLUSION -- The interim results show an improvement of disease burden in chronic migraine patients treated with erenumab.

Monthly Migraine Days (MMD)



Headache Impact Test-6 (HIT6)

